Antibodies Archives

News and Trends 20 Nov 2015

Biotech of the week: Opsona Therapeutics, The Leading Irish Immuno-Oncology Biotech

This week we say farewell to Austria and head North-West, across the United Kingdom and land in the Emerald Isle, Ireland, where we arrive at our destination, Dublin. The capital city of Ireland is the home of the very famous Irish dry stout, Trinity College (plus its stunning library) and a nearly 900-year-old cathedral. It is […]

November 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 23 Oct 2015

#Sorry: The World-leading Oncology Company fails in Phase III

Antibody Drug Conjugate is a smart way to improve chemotherapy. That is the strategy of Roche / Immunogen‘s drug Kadcyla®, which has just failed in Phase III clinical trial to extend its indications. Here are the facts… Antibody Drug Conjugate is at the boundary between chemical and biological drug. The principle is pretty simple; once the antibody fixes to […]

October 23, 2015 - 2 minutesmins - By Jerome Topsent

News and Trends 22 Oct 2015

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

ArGEN-X from Ghent (BE) and Breda (NL) has initiated its phase I human trials for Auto-immune diseases such as systemic lupus erythmatosus (SLE) – a rare chronic disease which has had little progress in the last 50 years. Here is the story behind SLE… As a rare disease, Dr. House and his fictional diagnostics team […]

October 22, 2015 - 4 minutesmins - By Dani Bancroft

In Depth 20 Oct 2015

The Ultimate Review on how Biotech Changed Cancer Treatment

You have roughly 50% chance of developing a cancer in your life and 25% of dying from it. How to cure it? Biotech played and will continue to play an essential role in Cancer, ranging from monoclonal antibodies, immuno-oncology, CAR-T and everything in between. Cancer is the degeneration of one type of cell within an […]

October 20, 2015 - 10 minutesmins - By Jerome Topsent

News and Trends 14 Oct 2015

Innate Pharma receives $5M from its Monster-deal with BMS

This milestone payment from Bristol-Myers Squibb is part of the lirilumab licensing agreement, the monster immuno-oncology deal of €408M ($465M) signed in July 2011. This payment was triggered by the dosing of the first patient in a phase II trial of the monoclonal antibody drug lirilumab, in combination with rituximab in patients with relapsed/refractory or […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Oct 2015

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

Adheron Therapeutics is a small California (US) biotech which has developed a phase I monoclonal antibody (mAb) therapy for inflammatory diseases such as Rheumatoid Arthritis. Using the mAb humanisation platform licensed from Abzena (a life Sciences group from Cambridge, UK), Adheron Therapeutics will now be acquired by Swiss giant Roche for €509M. Abzena, based in […]

October 12, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 8 Oct 2015

Rabbit Antibodies proven to be more specific than Mice in Immuno-oncology PD-L1 Research

Abcam is a Cambridge (UK) Biotech who have developed a monoclonal antibody (mAB) production platform from rabbits. This platform is developed for a much more specific immunohistochemical alternative to the traditional Rodent equivalents. Now the most recent generation of mAbs from this platoform is able to detect PD-L1 tumor proteins for immuno-oncology research. The conventional […]

October 8, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

Manfred Horst on MSD, Biosimilars, KEYTRUDA and his Company’s rich history

Manfred Horst is a Director Business Development Europe and working from an office at MSD France, the French affiliate of MSD which has its HQ in New Jersey (and is known as Merck & Co. in the US). MSD is one of the biggest pharmaceutical companies in the world with a 2014 revenue of €37.4Bn and €6.4Bn […]

October 5, 2015 - 6 minutesmins - By Julie Lellouche

News and Trends 29 Sep 2015

Could an Alpaca’s monoclonal antibodies be used to treat an ultra-rare blood disease?

Ablynx‘s Nanobody platform has used the smaller than human monoclonal antibodies from an alpaca to develop the phase III Orphan designated drug Caplacizumab. A phase III study ‘Hercules’ is now pioneering Caplacizumab as the first ever anti-Von Willebrand factor (vWF) nanobody for treating an ultra-rare blood clotting disorder. Caplacizumab is a pioneering monoclonal antibody (mAb) […]

September 29, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 28 Sep 2015

Sanofi and Regeneron’s Praluent succeeds at final hurdle with EU authorisation

Regeneron (NY, USA) has finally brought alirocumab (trade name Praluent) to the finish line with collaborator Sanofi, today announcing that the European commission has granted its hypercholesterolemia drug a marketing license for the EU. Having already been approved by the FDA in July, this completes Praluent’s launch into the Western pharma market. New-York based Regeneron […]

September 28, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 25 Sep 2015

Roche’s patent halts an Amgen biosimilar debut

Amgen has had great success with its Avastin biosimilar, used as an inhibitor of angiogenesis in tumor growth. However, despite smashing the phase III trials, the Amgen-Allergan partnership still has to wait until 2022 for Roche’s European Avastin patent to expire. Amgen partnered up with Dublin based Allergan (Ireland) for a comprehensive oncology biosimilars pipeline […]

September 25, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 11 Sep 2015

Cambridge Love Triangle: Leading Biotechs Abcam and Horizon finally collaborate together

This is the story of how Abcam and Horizon fell in collaborative-biotech-love and finally came together to partner up on antibody research. Whilst doing his post-doc at University of Cambridge, Jonathan Milner had an idea to improve how antibodies could be produced for researchers around the World. Thus, he founded the company Abcam in 1998. Over […]

September 11, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Antibodies

Biotech of the week: Opsona Therapeutics, The Leading Irish Immuno-Oncology Biotech

#Sorry: The World-leading Oncology Company fails in Phase III

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

The Ultimate Review on how Biotech Changed Cancer Treatment

Innate Pharma receives $5M from its Monster-deal with BMS

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

Rabbit Antibodies proven to be more specific than Mice in Immuno-oncology PD-L1 Research

Manfred Horst on MSD, Biosimilars, KEYTRUDA and his Company’s rich history

Could an Alpaca’s monoclonal antibodies be used to treat an ultra-rare blood disease?

Sanofi and Regeneron’s Praluent succeeds at final hurdle with EU authorisation

Roche’s patent halts an Amgen biosimilar debut

Cambridge Love Triangle: Leading Biotechs Abcam and Horizon finally collaborate together

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!